Prasinezumab vs Traditional Treatments: What's Different? скачать в хорошем качестве

Prasinezumab vs Traditional Treatments: What's Different?

Prasinezumab (Investigational) medicine for Parkinson’s disease currently in research, an alpha-synuclein monoclonal antibody targeting Lewy bodies/Lewy neurites. PASADENA & PADOVA trial results, what “missed the primary endpoint” means, and what Phase 3 could mean for disease-modifying treatment. Welcome to Rx Explained! In this video, Emily Carter explains Prasinezumab a potential disease-modifying therapy for Parkinson’s disease designed to bind misfolded alpha-synuclein protein aggregates. She breaks down the science (dopamine vs protein misfolding), why levodopa helps symptoms but doesn’t stop progression, and the honest read on the clinical data so far from PASADENA and PADOVA, including the signals researchers are watching as the program moves toward Phase 3 development. ✅ What You’ll Learn 💊 What Prasinezumab is and why it’s labeled “Investigational” 🧠 Parkinson’s: dopamine loss and protein misfolding (alpha-synuclein) 🧬 How antibodies may bind/tag aggregated proteins (the theory) 📊 PASADENA & PADOVA: key outcomes, endpoints, and “signals” 🗓️ What’s next: Phase 3 timelines and what to realistically expect 📌 Helpful Links 🔗 All My Resources & Recommendations: https://lnk.bio/rxexplained1 👉 Subscribe for future Parkinson’s trial updates explained in plain English. Video Chapters 00:00 Introduction 00:39 The Timed Dose Reality (Coffee & Tremor) 01:05 What Is Prasinezumab (Investigational)? 01:15 Why Levodopa Helps But Doesn’t Slow Progression 01:41 Parkinson’s: Not Just Dopamine (Protein Misfolding) 01:48 Alpha-Synuclein + Lewy Bodies/Neurites Explained 02:03 How Prasinezumab Is Designed To Work 02:27 PASADENA & PADOVA Trial Results (What The Data Shows) 03:00 What’s Next: Phase 3 + Timelines 03:52 Conclusion #Prasinezumab #ParkinsonsDisease #AlphaSynuclein #LewyBodies #ClinicalTrials #PASADENA #PADOVA #Levodopa #DiseaseModifyingTherapy #RxExplained #health